GlassScriptPhysician profile
Nebu Koshy
NPI 1679784524
$26,084.33
in general payments reported to CMS, 2019-2025
36 companies · $924 in 2025
The $924 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $5,706 · 2021: $233 · 2022: $672 · 2023: $4,567 · 2024: $490 · 2025: $924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,200 · Food and Beverage: $2,549 · Education: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,200.00 |
| Food and Beverage | $2,548.54 |
| Education | $231.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19,117.30 | 2019-2025 | Xospata, Cresemba |
| Cti Biopharma Corp. | $3,245.08 | 2023 | Vonjo |
| Incyte Corporation | $560.54 | 2019-2025 | Monjuvi, Jakafi, Niktimvo |
| Celgene Corporation | $318.64 | 2020-2025 | Reblozyl, Breyanzi |
| Abbvie INC. | $311.33 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.11 | 2019-2025 | Livtencity |
| Janssen Scientific Affairs, LLC | $274.20 | 2019-2025 | Darzalex, Carvykti |
| Legend Biotech USA INC. | $164.37 | 2023-2024 | Carvykti |
| Merck Sharp & Dohme LLC | $147.82 | 2021-2025 | Prevymis |
| Janssen Biotech, INC. | $146.49 | 2019-2024 | Tecvayli, Talvey, Darzalex |
| Novartis Pharmaceuticals Corporation | $144.26 | 2023-2025 | |
| Adc Therapeutics America, INC. | $127.37 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $117.81 | 2022-2023 | |
| Sanofi-Aventis U.S. LLC | $107.64 | 2023-2025 | |
| Pfizer INC. | $99.11 | 2023 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacyclics LLC, An Abbvie Company | $98.00 | 2023 | Imbruvica |
| Genzyme Corporation | $90.81 | 2020-2024 | |
| Kite Pharma, INC. | $87.72 | 2024-2025 | Yescarta |
| Glaxosmithkline, LLC. | $69.05 | 2022-2025 | Ojjaara |
| Alexion Pharmaceuticals, INC. | $66.34 | 2023 | Ultomiris |
| Acrotech Biopharma INC. | $65.85 | 2022 | |
| Gamida Cell INC. | $56.26 | 2023-2025 | Omisirge |
| Sobi, INC | $51.17 | 2022-2023 | |
| Morphosys, US INC. | $45.51 | 2023 | Monjuvi |
| Amgen INC. | $42.24 | 2019-2020 | |
| Karyopharm Therapeutics INC. | $40.35 | 2023-2024 | Xpovio |
| Rigel Pharmaceuticals, INC. | $39.71 | 2022-2023 | Rezlidhia, Tavalisse |
| Adaptive Biotechnologies Corporation | $28.87 | 2024 | Clonoseq |
| Seagen INC. | $28.79 | 2019-2022 | |
| Menarini Silicon Biosystems, INC. | $23.35 | 2025 | |
| Autolus INC | $23.19 | 2025 | |
| Agios Pharmaceuticals, INC. | $17.81 | 2024 | |
| Daiichi Sankyo INC. | $16.48 | 2023 | |
| Invivyd INC | $16.24 | 2025 | Pemgarda |
| Astrazeneca Pharmaceuticals LP | $15.52 | 2023 | Calquence |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nebu Koshy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.